Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151073 · ClinicalTrials.gov registry record · Phase 2
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00151073 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 28 participants.
The verdict
NCT00151073, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
Interventions
- DRUG Docetaxel
- DRUG Zoledronic acid
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151073
The ClinicalTrials.gov registry entry for NCT00151073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00151073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151073 about?
NCT00151073 is a clinical study titled "Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate". Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
What is the current status of trial NCT00151073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2002-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00151073?
The interventions under investigation include: Docetaxel (DRUG), Zoledronic acid (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT00151073?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.